Originally published as JCO Early Release 10.1200/JCO.2006.10.1949 on April 2 2007

This Article Full Text Full Text (PDF) Publisher's Note Erratum (v25,p4512) Erratum (v25,p4512) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Loblaw, D. A. Articles by Scher, H. I. Search for Related Content PubMed PubMed Citation Articles by Loblaw, D. A. Articles by Scher, H. I.

Initial Hormonal Management of Androgen-Sensitive Metastatic, Recurrent, or Progressive Prostate Cancer: 2007 Update of an American Society of Clinical Oncology Practice Guideline

D. Andrew Loblaw, Katherine S. Virgo, Robert Nam, Mark R. Somerfield, Edgar Ben-Josef, David S. Mendelson, Richard Middleton, Stewart A. Sharp, Thomas J. Smith, James Talcott, Maryellen Taplin, Nicholas J. Vogelzang, James L. Wade, III, Charles L. Bennett, Howard I. Scher

From the American Society of Clinical Oncology, Alexandria, VA

Address reprint requests to American Society of Clinical Oncology, 1900 Duke St, Ste 200, Alexandria, VA 22314; e-mail: guidelines{at}asco.org

Purpose: To update the 2004 American Society of Clinical Oncology (ASCO) guideline on initial hormonal management of androgen-sensitive, metastatic, recurrent, or progressive prostate cancer (PCa).

Methods: The writing committee based its recommendations on an updated systematic literature review. Recommendations were approved by the Expert Panel, the ASCO Health Services Committee, and the ASCO Board of Directors.

Results: Seven randomized controlled trials (four new), one systematic review, one meta-analysis (new), one Markov model, and one delta-method 95% CI procedure for active controlled trials (new) informed the guideline update.

Recommendations: Bilateral orchiectomy or luteinizing hormone–releasing hormone agonists are recommended initial androgen-deprivation treatments (ADTs). Nonsteroidal antiandrogen monotherapy merits discussion as an alternative; steroidal antiandrogen monotherapy should not be offered. Combined androgen blockade should be considered. In metastatic or progressive PCa, immediate versus symptom-onset institution of ADT results in a moderate decrease (17%) in relative risk (RR) for PCa-specific mortality, a moderate increase (15%) in RR for non–PCa-specific mortality, and no overall survival advantage. Therefore, the Panel cannot make a strong recommendation for early ADT initiation. Prostate-specific antigen (PSA) kinetics and other metrics allow identification of populations at high risk for PCa-specific and overall mortality. Further studies must be completed to assess whether patients with adverse prognostic factors gain a survival advantage from immediate ADT. For patients electing to wait until symptoms for ADT, regular monitoring visits are indicated. For patients with recurrence, clinical trials should be considered if available. Currently, data are insufficient to support use of intermittent androgen blockade outside clinical trials.

published online ahead of print at www.jco.org on April 2, 2007.

Approved by the Board on November 2, 2006.

Authors’ disclosures of potential conflicts of interest and author contributions are found at the end of this article.

This article has been cited by other articles:

				D. N Howard, C. Chambers, and F. Cusano Efficacy vs. effectiveness -- docetaxel and prednisone in hormone refractory prostate cancer Journal of Oncology Pharmacy Practice, March 1, 2008; 14(1): 45 - 49. [Abstract] [PDF]

				W. Arap, M. Trepel, B. R. Zetter, and R. Pasqualini Meeting Report: Innovations in Prostate Cancer Research Cancer Res., February 1, 2008; 68(3): 635 - 638. [Full Text] [PDF]

				S. Tomioka, M. Shimbo, Y. Amiya, H. Nakatsu, S. Murakami, and J. Shimazaki Outcome of Patients with Hormone-Refractory Prostate Cancer: Prognostic Significance of Prostate-Specific Antigen-Doubling Time and Nadir Prostate-Specific Antigen Jpn. J. Clin. Oncol., January 1, 2008; 38(1): 36 - 42. [Abstract] [Full Text] [PDF]

				K. I. Pritchard Adjuvant Endocrine Therapy of the Future: Potential and Possibilities ASCO Educational Book, January 1, 2008; 2008(1): 18 - 23. [Abstract] [Full Text] [PDF]

				ASCO Practice Guidelines for Initial Hormonal Management of Prostate Cancer Journal Watch Oncology and Hematology, May 14, 2007; 2007(514): 3 - 3. [Full Text]

				2007 Update of ASCO Practice Guideline for the Initial Hormonal Management of Androgen-Sensitive Metastatic, Recurrent, or Progressive Prostate Cancer: Guideline Summary J. Oncol. Pract, May 1, 2007; 3(3): 175 - 177. [Full Text] [PDF]